---

General Pathology - Topic-Wise Complete Guide from Robbins

---

🔬 TOPIC 1: INTRODUCTION TO PATHOLOGY

• Gross and microscopic morphology (appearance of cells/tissues)
• Molecular changes (genes and proteins)
• Biochemical alterations in body fluids (blood, urine)

---

🔬 TOPIC 2: OVERVIEW OF CELLULAR RESPONSES TO STRESS

Normal stress → ADAPTATION (new steady state, cell survives)
Mild/moderate injury → REVERSIBLE INJURY (can recover)
Severe/persistent injury → IRREVERSIBLE INJURY → CELL DEATH

---

🔬 TOPIC 3: CAUSES OF CELL INJURY

Major Categories:

1. Hypoxia and Ischemia
   • Hypoxia = oxygen deficiency
   • Ischemia = reduced blood supply (also reduces nutrients)
   • Most common causes of cell injury
2. Physical agents - mechanical trauma, extremes of temperature, radiation, electrical injury, sudden changes in atmospheric pressure
3. Chemical agents - glucose, salt (in high concentrations), oxygen, poisons, environmental pollutants, herbicides, insecticides, carbon monoxide, asbestos
4. Infectious agents - viruses, bacteria, fungi, parasites. Range from viruses that subvert cell functions to bacteria releasing toxins or directly invading cells.
5. Immunologic reactions - autoimmune diseases, reactions to infections, hypersensitivity
6. Genetic abnormalities - congenital malformations (trisomy 21), metabolic defects (sickle cell disease), increased susceptibility to disease
7. Nutritional imbalances - protein-calorie malnutrition, vitamin deficiencies, excess lipids/calories leading to obesity, diabetes, vascular disease
8. Aging - telomere shortening, DNA damage accumulation, reduced repair capacity

---

🔬 TOPIC 4: SEQUENCE OF EVENTS IN CELL INJURY

A. Reversible Cell Injury

• Cellular swelling - first manifestation of almost all forms of injury; caused by failure of energy-dependent ion pumps → Na⁺ influx → water enters cell
• Fatty change (steatosis) - occurs in cells involved in fat metabolism (hepatocytes, myocardial cells); manifests as lipid vacuoles within the cytoplasm
• Clumping of nuclear chromatin (pyknosis, early)
• Plasma membrane blebbing - cytoplasmic blebs form at membrane surface
• Mitochondrial swelling - with amorphous densities (flocculent) in the matrix
• Dilated ER with loss of ribosomes
• Myelin figures in cytoplasm (derived from damaged membranes)

Key histological marker: Loss of nuclear membrane and cytoplasmic blebs are early signs; once mitochondrial permeability transition pore opens irreversibly, the cell is doomed.

B. The Point of No Return

• Mitochondrial membrane permeability transition (MPT) becomes irreversible
• Loss of membrane phospholipids (phospholipases activated by rising Ca²⁺)
• Cytoskeletal disruption
• Loss of plasma membrane integrity

1. Inability to generate ATP even after correction of hypoxia
2. Profound disturbances in membrane function

---

🔬 TOPIC 5: CELL DEATH - NECROSIS

Definition

Key Morphologic Features of Necrosis:

Patterns of Tissue Necrosis:

• Cardiac troponin (released from necrotic cardiomyocytes) → marker of MI
• Alkaline phosphatase (bile duct epithelium) → liver damage marker
• Transaminases (hepatocytes) → hepatocellular injury

---

🔬 TOPIC 6: CELL DEATH - APOPTOSIS

Definition

Key Features (contrast with necrosis):

Causes of Apoptosis:

• Normal embryonic development (limb modeling)
• Turnover of proliferative tissues (intestinal epithelium, lymphocytes)
• Involution of hormone-dependent tissues (endometrium)
• Decline of leukocytes at end of immune responses
• Elimination of self-reactive lymphocytes (central tolerance)

• DNA damage (radiation, cytotoxic drugs, free radicals) - p53 accumulates → apoptosis
• Accumulation of misfolded proteins (ER stress)
• Cell injury in viral infections
• Pathologic atrophy of organs after duct obstruction (pancreas, kidney)

Mechanisms of Apoptosis:

• Regulated by the BCL2 family
• Proapoptotic: BAX, BAK, BAD, BIM, BID (form pores in mitochondria)
• Antiapoptotic: BCL2, BCL-XL (plug the pores)
• When proapoptotic signals win: cytochrome c leaks out → activates APAF-1 → caspase-9 → executioner caspases (3, 7)
• Triggers: loss of growth factors, DNA damage, oxidative stress, misfolded proteins

• Death receptors on cell surface: FAS (CD95), TNF receptor
• Ligand binding (FasL, TNF) → adaptor proteins (FADD) → caspase-8 → executioner caspases
• Perforin/granzyme B pathway: cytotoxic T-lymphocytes release granzyme B → directly activates caspases

• Caspases 3 and 7 activate DNase → DNA laddering (180-bp fragments)
• Cytoskeleton degraded → cell shrinks, buds off into apoptotic bodies
• "Eat-me" signals (phosphatidylserine flipped to outer leaflet) → phagocytosis

BCL2 and cancer: BCL2 overexpression (e.g., follicular lymphoma - t(14;18)) prevents apoptosis, allowing tumor cell survival.

---

🔬 TOPIC 7: AUTOPHAGY

• A double-membrane vacuole (autophagosome) engulfs cytoplasmic components
• Fuses with lysosome → autolysosome → enzymatic digestion → nutrient recycling
• Regulated by mTOR (inhibits autophagy) and ATG family genes (promote it)

• Cell survival under starvation
• Clearing damaged organelles and protein aggregates
• Implicated in aging, neurodegeneration (Parkinson's - clears damaged mitochondria via mitophagy), cancer

---

🔬 TOPIC 8: MECHANISMS OF CELL INJURY

1. Mitochondrial Dysfunction

• ATP depletion → failure of Na/K-ATPase → cellular swelling, ER dysfunction, reduced protein synthesis
• Oxidative phosphorylation impaired → switch to anaerobic glycolysis → lactic acidosis
• Cytochrome c release → apoptosis trigger

2. Oxidative Stress (Reactive Oxygen Species - ROS)

• Normal oxidative phosphorylation (O₂ → superoxide O₂•⁻)
• Xanthine oxidase (in ischemia-reperfusion)
• NADPH oxidase in leukocytes (respiratory burst, kills bacteria)
• Cytochrome P-450 reactions
• Ionizing radiation (water radiolysis)

• Superoxide dismutase (SOD) - O₂•⁻ → H₂O₂
• Catalase (peroxisomes) - H₂O₂ → H₂O + O₂
• Glutathione peroxidase (cytosol/mitochondria) - H₂O₂ → H₂O
• Antioxidants: Vitamin E, vitamin C, beta-carotene

• Lipid peroxidation - membrane damage (especially double bonds in polyunsaturated fatty acids)
• Protein oxidation - cross-linking → degradation of key enzymes
• DNA lesions - single/double-strand breaks → mutations or apoptosis

3. Membrane Damage

4. Disturbance in Calcium Homeostasis

• Normally cytosolic Ca²⁺ is very low (10⁻⁷ M)
• Injury → Ca²⁺ influx from outside AND release from ER/mitochondria
• Elevated Ca²⁺ activates:
  • Phospholipases → membrane damage
  • Proteases → cytoskeletal breakdown
  • Endonucleases → nuclear chromatin/DNA damage
  • ATPases → ATP depletion

5. Endoplasmic Reticulum (ER) Stress

• Accumulation of misfolded proteins triggers Unfolded Protein Response (UPR)
• UPR activates CHOP and caspase-12 (proapoptotic)
• Seen in: diabetes (misfolded insulin), Alzheimer's (A-beta aggregates), Parkinson's (alpha-synuclein)

6. DNA Damage

• Genotoxic chemicals, radiation, free radicals cause DNA breaks
• p53 activated → cell cycle arrest (to allow repair) or apoptosis (if irreparable)
• Accumulated mutations → cancer

---

🔬 TOPIC 9: CLINICOPATHOLOGIC EXAMPLES OF INJURY

Ischemia-Reperfusion Injury

• Paradox: restoring blood flow to ischemic tissue causes additional injury
• Mechanisms:
  • New ROS burst on reoxygenation (xanthine oxidase, electron transport chain)
  • Ca²⁺ influx → mitochondrial permeability transition
  • Complement system activation
  • Leukocyte influx → more ROS + proteases + cytokines
• Clinically important in: myocardial infarction thrombolysis, organ transplantation, stroke reperfusion

Toxic Cell Injury

• Mercury chloride → binds sulfhydryl groups of membrane proteins → inhibits ATP-dependent transport
• Diphtheria toxin → inhibits protein synthesis
• Anthrax toxin → promotes water influx, degrades MAP kinases

• Carbon tetrachloride (CCl₄) → CCl₃• (free radical) → phospholipid peroxidation → ER damage → fatty liver → cell death
• Acetaminophen (at overdose) → P-450 converts to toxic intermediate → acute liver failure (leading cause of acute liver failure in the US)

---

🔬 TOPIC 10: CELLULAR ADAPTATIONS TO STRESS

Types of Adaptation:

Pathologic Hypertrophy (Cardiac Example):

• Triggers: pressure overload (hypertension), volume overload, growth factors (IGF-1)
• Signal transduction: mechanical sensors → G-protein-coupled receptors → PI3K/AKT and MAPK pathways
• Re-expression of fetal gene program (β-myosin heavy chain instead of α)
• Long-term: can decompensate → heart failure (fibrosis, myocyte death, impaired contractility)

Pathologic Hyperplasia:

• Driven by growth factors (EGF, PDGF, FGF) or hormones
• Distinct from neoplasia: hyperplasia remains under normal regulatory control; growth ceases when stimulus removed
• But hyperplastic epithelium can become a substrate for malignant transformation

Atrophy - Mechanisms:

• Ubiquitin-proteasome pathway - dominant in protein catabolism
• Autophagy - digestion of organelles
• Cell signaling: decreased IGF-1/PI3K/AKT → increased FOXO transcription factors → ubiquitin ligases (MAFbx/atrogin-1, MuRF1)

Metaplasia:

• Driven by reprogramming of stem cells via altered signaling
• Example: Barrett esophagus - normal squamous epithelium → intestinal columnar epithelium (goblet cells) in response to chronic acid reflux
• Significance: if metaplastic epithelium undergoes additional mutations → can progress to dysplasia → cancer

---

🔬 TOPIC 11: INTRACELLULAR AND EXTRACELLULAR DEPOSITIONS

A. Intracellular Accumulations

Lipofuscin = indigestible membrane phospholipid residues; accumulates in aging neurons, cardiomyocytes, liver. Also called "wear and tear" pigment.

B. Extracellular Deposits - Pathologic Calcification

• Calcium deposits in dead or dying tissue (normal serum Ca²⁺)
• Mechanism: phosphatases released from dead cells liberate phosphate groups → bind calcium
• Examples: atheromatous plaques, caseous TB necrosis, fat necrosis, dead parasites, old infarcts, calcified heart valves
• Appearance: gritty, chalky white deposits

• Calcium deposits in normal tissue due to hypercalcemia (elevated serum Ca²⁺)
• Causes: hyperparathyroidism, vitamin D excess, sarcoidosis, Paget disease, bone metastases
• Sites: interstitial tissues of kidney (nephrocalcinosis), stomach, blood vessels, cornea, lungs
• Appearance: fine basophilic deposits; may compromise organ function

---

🔬 TOPIC 12: CELLULAR AGING

Mechanisms of Aging:

• Telomeres are repetitive DNA sequences (TTAGGG) at chromosome ends; protect chromosomes from recombination and degradation
• DNA polymerase cannot fully replicate the ends → telomeres shorten with each cell division
• Short telomeres → p53-mediated cell senescence or apoptosis
• Cancer cells reactivate telomerase to maintain telomere length (immortality)
• Premature aging syndrome: Dyskeratosis congenita (telomerase mutations)

• ROS from normal metabolism damage proteins, lipids, DNA
• Imperfect repair → accumulated mutations
• Mitochondrial DNA especially vulnerable (lacks histones, close to ROS source)

• Misfolded proteins accumulate with age (reduced chaperone function, impaired proteasome activity)
• Link to: Alzheimer's (amyloid and tau), Parkinson's (alpha-synuclein), Huntington's (polyglutamine aggregates)

• Hayflick limit: normal somatic cells can divide only ~50-60 times
• Senescent cells show: growth arrest, resistance to apoptosis, pro-inflammatory secretome (SASP - Senescence-Associated Secretory Phenotype)
• SASP factors promote chronic low-grade inflammation ("inflammaging")

• Altered histone modifications and DNA methylation patterns with age
• Change gene expression profiles

• Sirtuins (SIRT1-7): deacetylases activated by caloric restriction; improve DNA repair, metabolism
• mTOR pathway: nutrient sensor; inhibiting mTOR (rapamycin) extends lifespan in animal models
• IGF-1/insulin signaling: reduced signaling → extended lifespan in C. elegans and mice

---

🔬 TOPIC 13: INFLAMMATION (Overview from Robbins)

Two Main Types:

Acute Inflammation - Key Steps:

• Initial transient vasoconstriction (seconds)
• Then vasodilation (histamine, prostaglandins) → increased blood flow → rubor (redness) + calor (heat)
• Increased vascular permeability → protein-rich fluid leaks out → tumor (swelling) = exudate
• Slowing of blood flow → stasis → margination of leukocytes

• Phagocytosis enhanced by opsonins (IgG, C3b)
• Phagosome + lysosome = phagolysosome → killing by:
  • Reactive oxygen species (O₂•⁻, H₂O₂, OH•) via NADPH oxidase (respiratory burst)
  • Reactive nitrogen species (NO) from iNOS
  • Myeloperoxidase (MPO) - converts H₂O₂ + Cl⁻ → hypochlorous acid (HOCl) - most powerful microbicidal mechanism
  • Elastase, collagenase, cathepsins (lysosomal enzymes)

CGD (Chronic Granulomatous Disease): NADPH oxidase mutation → recurrent infections with catalase-positive organisms (S. aureus, Aspergillus) → granuloma formation.

Chemical Mediators of Inflammation:

Arachidonic Acid Pathway (Key for exams):

Membrane phospholipids
         ↓ (phospholipase A2, blocked by steroids/lipocortin)
Arachidonic acid
    ↙               ↘
COX pathway        LOX pathway
(blocked by NSAIDs) (blocked by zileuton)
    ↓                    ↓
PGH2 → PGE2, PGI2    5-HPETE → LTB4 (chemotaxis)
         TXA2                  → LTC4/D4/E4 (SRS-A, bronchoconstriction)

Outcomes of Acute Inflammation:

1. Resolution - complete restoration; edema absorbed, dead cells cleared
2. Abscess formation - if pyogenic organisms
3. Fibrosis/scarring - if tissue destroyed or can't regenerate
4. Chronic inflammation - if stimulus persists or is poorly degradable

Chronic Inflammation:

• Key cell: Macrophage (derived from monocytes)
  • Classically activated (M1): IFN-γ, LPS → pro-inflammatory, microbicidal
  • Alternatively activated (M2): IL-4, IL-13 → anti-inflammatory, tissue repair
• Granulomatous inflammation = specialized form; macrophages fuse to form epithelioid cells and giant cells (Langhans, foreign body type)
  • Causes: TB, leprosy, sarcoidosis, Crohn's, foreign bodies, fungi
  • Caseating granulomas: TB (central caseous necrosis surrounded by epithelioid cells, Langhans giant cells, lymphocytes)
  • Non-caseating granulomas: sarcoidosis, Crohn's disease

Systemic Effects of Inflammation (Acute Phase Response):

• Fever: IL-1, TNF, IL-6 → cyclooxygenase in hypothalamus → PGE2 → raises temperature set point
• Acute phase proteins: CRP, fibrinogen, serum amyloid A (SAA), haptoglobin, ferritin (synthesized by liver, stimulated by IL-6)
  • CRP binds phospholipids on bacteria → opsonization + complement activation
  • Fibrinogen causes rouleaux → elevated ESR
• Leukocytosis: IL-1 and TNF accelerate WBC release from marrow; G-CSF, M-CSF
  • Bacterial → neutrophilia (with band cells = "left shift")
  • Viral → lymphocytosis
  • Allergic/parasitic → eosinophilia
• Septic shock: massive TNF + IL-1 release → DIC, hypotension, multi-organ failure

---

🔬 TOPIC 14: TISSUE REPAIR AND WOUND HEALING

Two Processes:

Cell Regenerative Capacity:

Steps in Wound Healing (Primary Intention):

1. Hemostasis (hours): platelets aggregate; fibrin clot forms; vasoconstriction
2. Inflammation (days 1-3): neutrophils first, then macrophages clear debris
3. Proliferation/Granulation tissue (days 3-14):
   • Angiogenesis (VEGF, FGF) - new capillaries
   • Fibroblasts migrate and proliferate (PDGF, FGF, TGF-β)
   • Collagen synthesis begins (Type III first, then Type I)
   • Granulation tissue = new capillaries + activated fibroblasts + loose connective tissue + macrophages (pink, vascular tissue that bleeds easily)
4. Remodeling (weeks to months):
   • Type III → Type I collagen (stronger)
   • Myofibroblasts (actin-expressing fibroblasts) cause wound contraction
   • MMPs (matrix metalloproteinases) degrade matrix; balanced by TIMPs
   • Maximum tensile strength: ~70-80% of original (never 100%)

Key Growth Factors in Repair:

Complications of Wound Healing:

---

🔬 TOPIC 15: HEMODYNAMIC DISORDERS

Edema

• Edema when: ↑ capillary hydrostatic pressure, ↓ plasma oncotic pressure (hypoalbuminemia), ↑ vascular permeability, lymphatic obstruction

• Anasarca - generalized edema
• Pleural effusion - fluid in pleural cavity
• Pericardial effusion - fluid around heart
• Pulmonary edema - most dangerous; left heart failure → fluid floods alveoli → impairs gas exchange

Hyperemia and Congestion

• Hyperemia (active): arteriolar dilation → increased blood flow (exercise, inflammation); tissue appears red
• Congestion (passive): impaired venous outflow; tissue appears bluish-red (cyanosis)
  • Acute lung congestion: red hepatization in pneumonia
  • Chronic lung congestion: "heart failure cells" (hemosiderin-laden macrophages in alveoli)
  • Chronic liver congestion: "nutmeg liver" (centrilobular congestion, periportal fatty change)

Hemorrhage

• Escape of blood from vessels
• Petechiae (1-2mm, capillary; thrombocytopenia, vasculitis)
• Purpura (>3mm; vasculitis, trauma)
• Ecchymosis (bruise; >1-2cm; tissue breakdown: hemoglobin → bilirubin → hemosiderin → "black eye" to yellow-green)
• Hematoma (collection within tissue)

Thrombosis

1. Endothelial injury - most important for arterial thrombosis; atherosclerosis, hypertension, smoking
2. Abnormal blood flow - turbulence (arterial) or stasis (venous); prevents dilution of clotting factors
3. Hypercoagulability - inherited (Factor V Leiden, prothrombin G20210A, antithrombin III deficiency, Protein C/S deficiency) or acquired (pregnancy, oral contraceptives, antiphospholipid syndrome, malignancy)

• Resolution (fibrinolysis by t-PA, plasmin)
• Organization and recanalization (vessel reconstituted)
• Propagation (growing larger)
• Embolism

Embolism

• Source: DVT in leg/pelvic veins
• Saddle embolism (at bifurcation of pulmonary trunk) → sudden death
• Most (~60-80%) are clinically silent
• Massive PE → right heart failure, sudden death, circulatory collapse
• Infarction only if circulation is compromised (10-15% of PEs)

Infarction

• 0-4h: No visible change (gross); wavy fibers (micro)
• 4-24h: Pallor; coagulative necrosis begins
• 1-3 days: Yellow-tan pallor; neutrophils infiltrate
• 3-7 days: Hyperemic border; macrophages
• 1-3 weeks: Red-yellow granulation tissue at margins
• 6 weeks+: White fibrous scar

Shock

1. Compensated (non-progressive): tachycardia, vasoconstriction, ADH/angiotensin II maintain BP
2. Decompensated (progressive): hypoxic injury accumulates; lactic acidosis; myocardial depression
3. Irreversible: cell death; even if BP restored → organ failure

---

🔬 TOPIC 16: NEOPLASIA (General Principles)

Definitions:

• Neoplasm = "new growth"; autonomous, purposeless proliferation that exceeds and is uncoordinated with normal tissue
• Benign: non-invasive, well-differentiated, slow-growing, non-metastatic
• Malignant (cancer): invasive, poorly differentiated, potentially metastatic

Benign vs Malignant:

Tumor Nomenclature:

• Teratoma = tumor with elements from >1 germ layer (mature = benign, immature = malignant)
• Hamartoma = disorganized but mature tissue native to that site (not truly neoplastic)
• Choristoma = normal tissue in abnormal location (e.g., pancreatic tissue in small intestine)

Hallmarks of Cancer (Hanahan & Weinberg):

1. Self-sufficiency in growth signals - oncogene activation (RAS, MYC, HER2)
2. Insensitivity to growth inhibitory signals - tumor suppressor loss (RB, p53)
3. Evasion of apoptosis - BCL2 overexpression, p53 loss
4. Limitless replicative potential - telomerase reactivation
5. Sustained angiogenesis - VEGF overexpression
6. Invasion and metastasis - E-cadherin loss, MMPs
7. Reprogramming of energy metabolism - Warburg effect (aerobic glycolysis)
8. Evasion of immune surveillance - PD-L1 expression, loss of MHC-I Enablers: Genomic instability, tumor-promoting inflammation

Carcinogens:

• Direct-acting: alkylating agents (nitrogen mustard, cyclophosphamide), acylating agents
• Indirect-acting (procarcinogens - need metabolic activation):
  • Polycyclic aromatic hydrocarbons (cigarette smoke, soot → lung/skin cancer)
  • Aromatic amines, azo dyes (β-naphthylamine → bladder cancer)
  • Aflatoxin B1 (Aspergillus flavus on grain/peanuts → hepatocellular carcinoma; G→T mutation in p53 codon 249)
  • Nitrosamines (stomach cancer)
  • Vinyl chloride → angiosarcoma of liver

• UV radiation (UV-B, 280-320nm) → pyrimidine dimers; nucleotide excision repair (NER) defect → xeroderma pigmentosum → skin cancer
• X-rays/gamma rays → double-strand DNA breaks

Oncogenes and Tumor Suppressor Genes:

p53 - The Guardian of the Genome:

• Most commonly mutated gene in human cancer (>50%)
• Activated by: DNA damage, oncogene activation, hypoxia, telomere erosion
• Functions: Cell cycle arrest (G1/S via p21), DNA repair, apoptosis (via PUMA/NOXA/BAX)
• Mutant p53: loses tumor suppressor function AND gains pro-oncogenic function (dominant negative)
• Li-Fraumeni syndrome: germline TP53 mutation → multiple cancers at young age

RB Pathway:

Growth signals → ↑ Cyclin D + CDK4/6 → Phosphorylates RB
Phospho-RB releases E2F → G1/S transition (cell proliferates)

p16 (CDKN2A) → Inhibits CDK4/6 → RB stays active → cell cycle arrest

Metastasis - Mechanisms:

1. Local invasion: degradation of basement membrane (MMPs, cathepsins); E-cadherin loss (key step); EMT (epithelial-to-mesenchymal transition)
2. Intravasation: entry into lymphatics or blood vessels
3. Survival in circulation: evade NK cells, immune surveillance; travel as emboli
4. Arrest in target organ: mechanical trapping; selectin-mediated adhesion
5. Extravasation: exit from vessel
6. Formation of micrometastasis
7. Colonization: establish vascular supply, adapt to new microenvironment ("seed and soil" hypothesis - Paget, 1889)

• Liver: colorectal, stomach, pancreatic, breast, lung
• Lungs: colorectal, breast, kidney, thyroid, Wilms tumor
• Brain: lung, breast, melanoma, kidney, colorectal ("Let Me Brain Kick Crazy")
• Bone: prostate, breast, lung, thyroid, kidney ("Prostates, Breasts Like The Kidneys")
  • Osteolytic: breast, lung, thyroid, kidney
  • Osteoblastic: prostate

Tumor Grading vs Staging:

Paraneoplastic Syndromes:

---

🔬 TOPIC 17: GENETIC DISORDERS (General Principles)

Types of Genetic Disorders:

1. Single-gene (Mendelian) - high-penetrance mutations in one gene
2. Chromosomal - structural or numerical abnormalities in chromosomes
3. Complex (multifactorial) - polygenic + environmental; low penetrance
4. Mitochondrial - maternal inheritance

Mutation Types and Effects:

Autosomal Dominant:

• One mutant allele sufficient for disease
• 50% chance of transmission
• Examples: Marfan, neurofibromatosis, Huntington, BRCA1/2, familial hypercholesterolemia, polycystic kidney disease (adult), achondroplasia

Autosomal Recessive:

• Both alleles must be mutant
• 25% recurrence risk for siblings
• Often enzyme deficiencies
• Examples: cystic fibrosis, PKU, sickle cell, thalassemia, hemochromatosis, Wilson disease, Gaucher disease

X-linked Recessive:

• Males affected; females carriers
• No male-to-male transmission
• Examples: Duchenne/Becker MD, hemophilia A/B, G6PD deficiency, Fabry, Hunter syndrome, fragile X

Chromosomal Disorders:

---

Summary Table: High-Yield General Pathology Points

---

---

---

🎓 Seminar Question Bank: Newer Hypolipidemic Drugs & Treatment Strategy

---

🔴 CATEGORY 1: Basic Science & Mechanisms (Most likely to be asked first)

---

PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) is a serine protease produced by hepatocytes. After LDL binds the LDL receptor (LDLR) on the hepatocyte surface, the LDLR-LDL complex is internalized. Normally, LDLR recycles back to the surface. PCSK9 binds the LDLR and escorts it to the lysosome for degradation, preventing recycling. More PCSK9 = fewer LDLRs = higher plasma LDL. Inhibiting PCSK9 allows LDLRs to recycle repeatedly → greater LDL clearance.

---

Trick question alert: Faculty often ask "If inclisiran targets mRNA inside the cell, how does it get there?" - Answer: It is conjugated to GalNAc (N-acetylgalactosamine), which is taken up by asialoglycoprotein receptors on hepatocytes - highly liver-specific delivery.

---

Bempedoic acid inhibits ATP-citrate lyase (ACL), an enzyme upstream of HMG-CoA reductase in the cholesterol synthesis pathway. ACL converts citrate to acetyl-CoA (the substrate for cholesterol synthesis) in the cytoplasm. It reduces cholesterol synthesis in the liver → upregulates LDLR via SREBP-2 → increased LDL clearance.

Why no myopathy: Bempedoic acid is a prodrug activated by very-long-chain acyl-CoA synthetase 1 (ACSVL1), an enzyme expressed in the liver but NOT in skeletal muscle. Therefore it accumulates in hepatocytes but not myocytes - avoiding the mitochondrial dysfunction that causes statin-related myopathy.

---

1. Inclisiran (double-stranded siRNA) enters hepatocytes via GalNAc-receptor mediated endocytosis
2. The antisense strand is incorporated into the RISC (RNA-Induced Silencing Complex)
3. RISC uses the antisense strand as a guide to bind complementary PCSK9 mRNA
4. The mRNA is cleaved and degraded
5. RISC is catalytic - one RISC complex can destroy multiple mRNA molecules → prolonged effect
6. Result: reduced PCSK9 protein synthesis → more LDLRs on hepatocyte surface → lower plasma LDL

---

Ezetimibe inhibits NPC1L1 (Niemann-Pick C1-Like 1) transporter in the intestinal brush border, blocking absorption of both dietary and biliary cholesterol. Reduced intestinal cholesterol delivery to the liver activates SREBP → upregulates LDLR and HMG-CoA reductase. Statins prevent the compensatory upregulation of HMG-CoA reductase - hence synergy. Ezetimibe alone reduces LDL by ~18%; combined with statin, reduces an additional 15-25% on top of statin effect.

---

Citrate from the TCA cycle is exported from mitochondria. ATP-citrate lyase (ACLY) cleaves it to oxaloacetate and acetyl-CoA in the cytoplasm. Acetyl-CoA is the starting substrate for:

• Cholesterol synthesis (via HMG-CoA → mevalonate)
• Fatty acid synthesis Bempedoic acid blocks this step, cutting the cytoplasmic acetyl-CoA supply for cholesterol biosynthesis.

---

🔴 CATEGORY 2: Clinical Pharmacology & Drug Details

---

---

Generally very well tolerated. The main adverse effects are:

• Injection site reactions (most common; erythema, pain, bruising)
• Nasopharyngitis, upper respiratory infections
• Flu-like symptoms
• Neurocognitive events - initially a concern from FOURIER/ODYSSEY; further analysis showed no significant increase in neurocognitive events with sustained very-low LDL
• Diabetes risk: not increased (unlike statins)
• No myopathy

Long-term safety: FOURIER Open Label Extension (OLE) showed sustained benefit and safety for up to 8+ years of evolocumab.

---

• Hyperuricemia and gout (10-25% increase in uric acid) - because bempedoic acid inhibits renal tubular uric acid secretion. Contraindicated in active gout.
• Tendon rupture (rare but FDA-flagged - black box warning for tendon effects; mechanism unclear)
• Elevated liver enzymes (transient)
• Anemia (mild)
• Does NOT cause myopathy (unlike statins)

---

• Hepatic steatosis (fat accumulation in liver) - transaminase elevation in ~30%
• GI side effects (diarrhea, nausea, abdominal pain) - mitigated by strict low-fat diet (<20% of calories from fat)
• Fat-soluble vitamin deficiency (vitamins A, D, E, K, linolenic acid) - must supplement
• Teratogenic - category X
• Available only through REMS (Risk Evaluation and Mitigation Strategy) program
• Only approved for homozygous FH (HoFH)

---

Evinacumab is a fully human monoclonal antibody against ANGPTL3 (Angiopoietin-like protein 3). ANGPTL3 inhibits lipoprotein lipase (LPL) and endothelial lipase, so blocking it increases LPL activity → accelerates clearance of TG-rich lipoproteins and LDL.

Key point: Evinacumab works independently of LDL receptors. This makes it uniquely valuable in homozygous FH where both LDL receptor alleles are non-functional (so PCSK9 inhibitors barely work in HoFH). Evinacumab reduces LDL by ~47% even in receptor-negative HoFH patients.

2025 ESC/EAS Guideline: Class IIa, Level B recommendation for HoFH aged ≥5 years not meeting LDL goals on maximum therapy. Given as monthly IV infusion (15 mg/kg).

---

• PCSK9 mAbs (evolocumab, alirocumab): Faster onset (days to 2 weeks), more titrable, can use q2w or monthly, slightly greater LDL reduction (~60-70%)
• Inclisiran: Twice-yearly dosing improves adherence (a huge real-world advantage); useful in patients with poor adherence to frequent injections; effect builds over ~3 months; similar long-term efficacy. ORION-8 trial confirmed durable LDL lowering over extended follow-up.
• Practical: Inclisiran is administered in a clinic setting (healthcare provider-administered), which actually enhances adherence. PCSK9 mAbs are patient self-administered.

---

🔴 CATEGORY 3: Clinical Trial Evidence (Faculty LOVE this)

---

Important nuance: FOURIER did not show mortality benefit; ODYSSEY OUTCOMES showed mortality benefit in patients with baseline LDL ≥100. This is a common discussion point.

---

CLEAR Outcomes (Nissen et al., NEJM 2023, PMID 36876740):

• Population: ~13,970 statin-intolerant patients with or at high risk for CVD
• Bempedoic acid 180 mg vs. placebo
• Result: Significant reduction in 4-component MACE (CV death, non-fatal MI, non-fatal stroke, coronary revascularization) - RRR 13%, HR 0.87 (p<0.001)
• Reduced non-fatal MI by 23%
• No reduction in CV death (secondary endpoint)
• LDL reduced by ~21% vs placebo
• Adverse effects: more gout (3% vs 1.5%), elevated uric acid; rare tendon rupture

This was the first cardiovascular outcomes trial specifically in statin-intolerant patients, establishing bempedoic acid as a viable option for this group.

---

• ORION-1: Phase 2 - confirmed dose-finding; biannual dosing established
• ORION-3/9/10/11: Phase 3 - inclisiran reduced LDL by 47-52% vs. placebo across heterogeneous populations (ASCVD, HeFH, high-risk primary prevention)
• ORION-8 (2024, Cardiovascular Research, PMID 38753448): Extended follow-up showing potent and durable LDL lowering over 4+ years with consistent twice-yearly dosing; no new safety signals
• VICTORION-difference (2026, Eur Heart J, PMID 40884558): Inclisiran-based strategy vs. usual care in hypercholesterolaemia
• VICTORION-Mono (2025, JACC, PMID 40392667): Inclisiran monotherapy in patients without ASCVD - confirmed safety and lipid lowering in primary prevention setting

Important gap: As of 2025-2026, no dedicated large-scale CVOT (like FOURIER) has completed for inclisiran. The ongoing ORION-4 trial is the outcomes trial (expected ~2026-2027).

---

IMPROVE-IT (2015): Simvastatin + ezetimibe vs. simvastatin alone in 18,000+ ACS patients. First trial to show that non-statin lipid lowering (ezetimibe) reduces cardiovascular events, validating the LDL hypothesis beyond statins. Established the "lower is better" principle. 6.4% RRR in primary endpoint over 7 years. NNT = 50. This trial opened the door for further combination therapy trials.

---

🔴 CATEGORY 4: Treatment Strategy & Guidelines

---

2025 update: LDL targets unchanged from 2019 ESC guidelines, but combination therapy pathways expanded; bempedoic acid and evinacumab formally added.

---

STEP 1: High-intensity statin (atorvastatin 40-80mg OR rosuvastatin 20-40mg)
            ↓ (if LDL goal not met)
STEP 2: Add ezetimibe 10 mg
            ↓ (if LDL goal not met; very high / extreme risk)
STEP 3: Add PCSK9 inhibitor (evolocumab or alirocumab)
           OR Inclisiran (especially if adherence is a concern)
            ↓ (special circumstances)
STEP 4: For HoFH: add evinacumab (ANGPTL3 inhibitor)
         For HoFH or severe HeFH: lomitapide
         LDL apheresis for refractory HoFH

STATIN-INTOLERANT patients:
→ Try alternative statin, lower dose, or different frequency (e.g., rosuvastatin 5mg alternate days)
→ If truly intolerant: bempedoic acid + ezetimibe (oral) OR PCSK9 inhibitor / inclisiran

2025 ESC Update: "The faster and lower, the better" - in ACS, start/intensify lipid-lowering during the index hospitalization, not weeks later.

---

This is a very high-risk patient (established ASCVD - post-MI). LDL is above target despite dual oral therapy. Next step:

• Add a PCSK9 inhibitor (evolocumab 140mg q2w or alirocumab 75-150mg q2w) OR
• Add inclisiran (if preferring less frequent dosing or adherence concern)
• Expected additional LDL reduction: 50-60%
• Expected final LDL: ~30-40 mg/dL (well within very high-risk target of <55)
• Counsel on injection site reactions; no need for routine monitoring of liver or muscle enzymes with PCSK9i

---

In HoFH with receptor-negative mutations, PCSK9 inhibitors may have minimal/no effect (as the receptor is absent). Options:

1. Evinacumab (ANGPTL3 mAb) - works receptor-independently; ~47% LDL reduction even in receptor-negative HoFH; monthly IV infusion (2025 ESC Class IIa, Level B)
2. Lomitapide - MTP inhibitor; reduces VLDL secretion; LDL ↓ ~40-50%; requires strict low-fat diet + fat-soluble vitamin supplementation; hepatotoxicity risk
3. LDL apheresis - extracorporeal removal every 1-2 weeks; reduces LDL 50-75% per session; gold standard for severe HoFH
4. Liver transplantation - replaces non-functional hepatic LDL receptors; rare last resort

---

• ACC/AHA (US): Risk-based approach; focuses on percentage reduction in LDL rather than specific numerical targets; uses Pooled Cohort Equations (PCE) for risk stratification; emphasizes 10-year ASCVD risk ≥7.5% as threshold for statin initiation
• ESC/EAS (Europe): Target-based approach; specific LDL-C numerical targets (as above) for each risk category; uses SCORE2/SCORE2-OP for risk assessment; more prescriptive about stepwise addition of non-statin drugs
• AACE (US endocrine): Even more aggressive targets; uses "extreme risk" category with LDL <40 mg/dL
• 2025 ESC: Adopted SCORE2/SCORE2-OP (replaces old SCORE), added bempedoic acid and evinacumab

---

1. First confirm true statin intolerance (rule out coincidental muscle disease, CK level, timing)
2. Try lower dose of same statin, or switch to rosuvastatin (lowest myopathy risk) or fluvastatin
3. Try alternate-day dosing of rosuvastatin
4. If truly intolerant to all statins:
   • Bempedoic acid ± ezetimibe (oral; no myopathy; CLEAR Outcomes proven CV benefit)
   • PCSK9 inhibitor (injectable; no myopathy; proven CV benefit in FOURIER/ODYSSEY)
   • Inclisiran (injectable; twice yearly)
   • Ezetimibe alone (modest LDL lowering ~18%)
   • Bile acid sequestrants (limited use due to GI side effects and drug interactions)

---

🔴 CATEGORY 5: Newer/Emerging Drugs (Cutting-Edge Questions)

---

Lerodalcibep is an oral small-molecule PCSK9 inhibitor (adnectin-based protein - not a monoclonal antibody). It binds PCSK9 and blocks its interaction with the LDL receptor, but is taken orally. Phase 2b data (MK-0616 trial, JACC 2023, PMID 36889610) showed robust LDL lowering (41-60%). This would be the first oral PCSK9 inhibitor if approved. AZD0780 (AstraZeneca) is another oral PCSK9 inhibitor in trials.

Significance: Oral route could dramatically improve access, adherence, and patient acceptability compared to injectables.

---

• Lp(a) = LDL-like particle with apolipoprotein(a) [apo(a)] covalently attached
• Levels are primarily genetically determined (90%); not significantly affected by diet/lifestyle
• Elevated Lp(a) >50 mg/dL (>105 nmol/L) = independent causal risk factor for ASCVD and aortic stenosis; up to 3x increased risk at 95th percentile
• Standard lipid-lowering therapies have minimal effect: statins don't lower it, ezetimibe ≤7%, bempedoic acid - no effect; PCSK9 inhibitors reduce Lp(a) by ~20-25%
• 2025 ESC/EAS: Measure Lp(a) at least once in every adult's lifetime

Emerging Lp(a)-specific therapies (not yet FDA-approved as of mid-2026):

• Pelacarsen (antisense oligonucleotide/ASO targeting apo(a) mRNA): ~80% Lp(a) reduction; Lp(a)HORIZON CVOT (phase 3) ongoing
• Olpasiran (siRNA targeting LPA gene): ~90%+ Lp(a) reduction; OCEAN(a) Outcomes trial ongoing
• Lepodisiran (siRNA, Eli Lilly - ALPACA trial at ACC 2025): up to 94% Lp(a) reduction - most potent in class; phase 3 outcomes trial being planned

---

---

Mipomersen is an antisense oligonucleotide (ASO) targeting apolipoprotein B-100 mRNA in hepatocytes, reducing hepatic production of apoB-containing lipoproteins (LDL, VLDL). Reduces LDL by ~25% in HoFH.

Rarely used because:

• Significant hepatotoxicity (hepatic steatosis in >50%, transaminase elevation)
• Flu-like injection site reactions and systemic effects
• Only approved in the US (not in Europe - EMA withdrew approval)
• Restricted to HoFH via REMS
• Superseded by better-tolerated agents (evinacumab)

---

🔴 CATEGORY 6: Special Populations & Tricky Scenarios

---

No. PCSK9 inhibitors (evolocumab, alirocumab) are Category C (US) and are generally avoided in pregnancy. Preclinical data shows no clear teratogenicity, but cholesterol is essential for fetal development. Statins are contraindicated in pregnancy (Category X). Ezetimibe is also not recommended. Bile acid sequestrants (cholestyramine) are the safest option as they are not systemically absorbed.

---

• Statins: Most are safe; pravastatin and fluvastatin preferred (least renal metabolism); rosuvastatin dose-adjusted in severe CKD
• Ezetimibe: Safe in CKD (no dose adjustment needed)
• PCSK9 inhibitors: No dose adjustment needed; safe in CKD; particularly valuable as CKD patients have high CV risk
• Fibrates: Caution; fenofibrate can increase serum creatinine (reduces tubular creatinine secretion); gemfibrozil avoided with statins (rhabdomyolysis risk)
• SHARP trial showed simvastatin + ezetimibe reduced vascular events in CKD

---

This is hypertriglyceridemia management, different from LDL-focused therapy:

1. Fibrates (fenofibrate, gemfibrozil) - PPARα agonists; TG ↓ 30-50%; first choice for severe hypertriglyceridemia
2. Omega-3 fatty acids (icosapent ethyl / Vascepa) - purified EPA 4g/day; TG ↓ 20-30%; REDUCE-IT trial showed 25% RRR in CV events in statin-treated patients with high TG (TG ≥150mg/dL + LDL 41-100mg/dL); approved for CV risk reduction
3. Niacin - largely fallen out of favor (AIM-HIGH, HPS2-THRIVE trials failed to show CV benefit when added to statin)
4. Volanesorsen (ASO against ApoC-III mRNA) - approved in Europe for familial chylomicronemia syndrome (TG >880mg/dL); reduces TG by ~70%; thrombocytopenia risk

---

• HoFH with LDL >500mg/dL refractory to maximum drug therapy
• HeFH with established ASCVD and LDL >160 mg/dL despite maximum drug therapy
• Lp(a) hyperlipoproteinemia (Lp(a) >60 mg/dL) with progressive ASCVD despite optimal LDL control
• Mechanism: extracorporeal removal of apoB-containing lipoproteins using selective adsorption columns (dextran sulfate or heparin columns)
• Performed every 1-2 weeks; reduces LDL by 50-75% per session but rebounds between sessions

---

🔴 CATEGORY 7: Classic "Trick" & Viva Questions

---

This is a major discussion point. Evidence:

• FOURIER and ODYSSEY achieved LDL as low as 20-30 mg/dL without significant harm
• FOURIER OLE: Patients with LDL consistently <20 mg/dL for 5+ years had no increase in hemorrhagic stroke, diabetes, neurocognitive impairment, or cancer
• Mendelian randomization studies of PCSK9 loss-of-function mutations (natural "experiment"): lifelong very-low LDL → lower ASCVD, no organ dysfunction
• Concern about hemorrhagic stroke with very low LDL has not been borne out in clinical trials
• Concern about adrenal function (cholesterol is a steroid precursor): adrenal steroidogenesis is maintained as adrenal glands synthesize their own cholesterol
• Current consensus: "Lower is better" with no established floor for LDL; the evidence supports LDL <20-25 mg/dL without harm

---

• Primary prevention: Patient has no established ASCVD; treatment aims to prevent first cardiovascular event; risk stratification (SCORE2/PCE) determines threshold for treatment; target LDL <100 mg/dL (moderate risk) to <70 mg/dL (high risk)
• Secondary prevention: Patient has established ASCVD (MI, stroke, PCI, CABG, PAD); much higher absolute risk; everyone should be on high-intensity statin; target LDL <55 mg/dL (very high risk); consider PCSK9 inhibitor early if not at goal

---

Even patients on optimal statin therapy who achieve LDL targets have residual CV risk (~50-60% of CV events occur despite statin therapy). This residual risk is attributable to:

1. Residual LDL risk (LDL still above target) → addressed by PCSK9 inhibitors, inclisiran, bempedoic acid
2. Triglyceride/remnant risk → addressed by icosapent ethyl (REDUCE-IT), fibrates
3. Lp(a) risk → currently no approved specific Lp(a) therapy; PCSK9 inhibitors have partial effect; investigational: pelacarsen, olpasiran, lepodisiran
4. Inflammatory risk (high-sensitivity CRP) → addressed by colchicine (LoDoCo2 trial), canakinumab (CANTOS trial)
5. Non-HDL/apoB as better markers than LDL-C alone for residual risk

---

Niacin increases HDL by 15-30%, reduces TG by 20-40%, reduces LDL by 10-20%, and reduces Lp(a) by 20-30% - an apparently ideal lipid profile. However:

• AIM-HIGH trial (2011): Niacin added to simvastatin + ezetimibe → no CV benefit, trial stopped early
• HPS2-THRIVE trial (2014): Niacin + laropiprant added to statin → no CV benefit; significantly increased adverse events (bleeding, infections, GI, new-onset diabetes, musculoskeletal)
• Conclusion: Raising HDL pharmacologically does not translate to CV benefit; the concept of "HDL hypothesis" failed. We now focus primarily on LDL and non-HDL lowering.

---

Major new recommendation: Initiate or intensify lipid-lowering therapy during the index ACS hospitalization ("the faster and lower, the better"):

• Start high-intensity statin immediately in all ACS patients regardless of baseline LDL
• If on statin already: add ezetimibe or PCSK9 inhibitor in-hospital
• Don't wait for outpatient follow-up
• Rationale: in-hospital initiation improves adherence; early LDL lowering may have pleiotropic effects on plaque stabilization; EPIC-stent, EVOLVE-ACS and other data support early initiation of PCSK9 inhibitors during ACS hospitalization

---

📋 Quick-Reference Summary for Viva

---

1. Mechanism of bempedoic acid not causing myopathy (ACSVL1 tissue specificity)
2. Why PCSK9 inhibitors work less well in HoFH (no receptors to spare)
3. Why evinacumab works even in receptor-negative HoFH (receptor-independent mechanism)
4. Why niacin failed despite a great lipid profile (HDL hypothesis failure)
5. The status of ORION-4 (inclisiran outcomes trial still ongoing) - be careful not to claim a completed CVOT for inclisiran
6. The Lp(a)-specific drug pipeline - highly topical in 2025-2026